Letters to the editor  by unknown
574 JACC Vol. 26, No. 2 
August 1995:574-6 
LE'[TERS TO THE EDITOR 
Patient Selection for Repair of 
Complete Atrioventricular Canal 
Guided by Echocardiography 
We read with interest he article by Zellers et al. (1) on the results of 
surgical repair of complete atrioventricular (AV) canal guided by 
echocardiography alone. Our group has favored this approach for 
A few points seem to us worth mentioning on the basis of our 
experience of>80 patients <1 year old with the complete form of AV 
canal who have undergone surgical repair guided by echocardiography 
alone at our institution. 
1) As we and other investigators have d.'.monstrated (4-6), 
significant differences exist between patients with and without 
Down syndrome and complete AV canal. Patients with Down 
syndrome are prone to early development ofpulmonary obstructive 
vascular disease (7), but show a rather monotonous arrangement of
intracardiac anomalies. Conversely, patients without Down syn- 
drome have a much higher prevalence of associated cardiac mal- 
formations, such as leR ventricular hypoplasia (4), additional 
ventricular septal defects (8), left ventricular outflow tract obstruc- 
tion (5), and from a strictly surgical viewpoint, often pose difficult 
problems in the repair of the left AV valve. We believe that patient 
selection is crucial when an infant with cor, plc,e AV canal is 
considered for surgical repair with echocardiography alone. Pa- 
tients without Down syndrome should be evaluated with a higher 
level of suspicion for associated anomalies and may well require 
cardiac catheterization for a complete preoperative assessment. 
This notion is unclear in the report by Zellers et ai. and we think it 
appropriate to stress its importance to the reader. 
2) In relation to calculation of pulmonary arteriolar esistance, 
ZeUers et al. (1) state that "hemodynamic information obtained at 
catheterization was not predictive of postoperative morbidity and 
mortality." Our experience confirms these findings; although ele- 
vated pulmonary vascular esistance is common, particularly in 
infants >6 months old, postoperative pulmonary hypertension is
rarely seen. Therefore, in this respect, surgical repair should be 
confidently offered to all patients <1 year old. It remains unclear 
whether this is also true for infants with Down syndrome and, like 
Zellers et al., we believe that the timing of an early repair is 
warranted for these patients. 
3) We agree with Zellers et al. that the patency of an arte::al duct 
is often equivocal on echocardiography. In our practice, the surgeon is 
alerted when a patent ductus arteriosus caamot be ruled out with the 
usual type of investigation and that the duct should be explored 
intraoperatively. 
4) Finally, we advise valuation of the systemic venous return to 
complete the preoperative evaluation. The surgeon should be aware 
of the persistence of a left superior vena cava in planning the 
operative strategy. This anatomic detail is best elucidated by the 
suprasternal short-axis view with the aid of color Doppler flow 
interrogation. 
Zellers et al. should be congratulated onthis important contribu- 
tion to the clarification of the role of echocardiography in indicating 
the surgical repair of complete AV canal. 
DUCCIO DI CARLO, MD 
BRUNO MARINO, MD 
Dipartimento Medico-Chirutgico di Cardiologia Pediatrica Ospedale 
Bambino Ges:, 
Rome 00165, Italy 
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Reply 
I thank Di Carlo and Marco for thek kind comments and for sharing 
their experience with us. Several of their points are well taken. 
I would agree that there is a difference in the anatomy of the 
atrioventricular (AV) septal defect in patients with and those without 
Down syndrome. Patients with AV septal defect but without Down 
syndrome do have a higher association of complicating intracardiac 
lesions, such as left ventricular outflow tract obstruction, unbalanced 
ventricular volume and commitment of the AV valves, and deficient 
AV valve tissue. However, in our study (1) we found that careful tram- 
thoracic echocardiographic examination using multiple windows de- 
fined these anatomic variants quite accurately. In fact, one of the 
reasons that we stopped performing cardiac atheterization in patients 
with AV septal defect is because angiographic imaging merely con- 
firmed our echocardiographic diagnosis but did not add very much to 
the definition of these anatomic variants. In addition, the typical 
hemodynamic information (intracardiac pressures, Op and Rp) did not 
preclude any of these patients from operative intervention. However, 
I would agree that cardiac catheterization should be considered if 
echocardiographic imaging is equivocal or not diagnostic, and we have 
found it particularly useful in patients with suspected pulmonary artery 
complications. 
I agree with Di Carlo and Marino that early repair of AV septal 
defect in Down syndrome iswarranted because of the early develop- 
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ment of pulmonary vascular obstructive disease seen in some patients. 
Although we were able to perform repair in children >6 months old 
with Down syndrome (usually because of late referral), our current 
policy is to undertake repair at 3 to 6 months of age, depending on the 
degree of congestive heart failure present. However, this policy is 
dependent on early referral. 
With regard to the diagnosis of a patent ductus arteriosus, I agree 
with the approach of Di Carlo and Marino. In fact, we state that same 
approach on page 1569 of our report (1). I think that this is the only 
logical approach to this problem. 
Finally. I agree that careful examination of the systemic venous 
return is important. Although we did not find anomalous ystemic 
venous return in our group of patients, we know that it can occur. In 
~,¢c'4 • p'e~i~¢¢a¢ deft ~f~gerr'~r ceaa cava ¢o a coronary s~hus can be 
easily missed or misinterpreted given the presence of a primum atrial 
septal defect in these patients. Our careful search involves 1) looldng 
for an enlarged coronary sinus because the majority of left superior 
venae cavae drain to the coronary sinus; 2) determining the presence 
or absence and the size of the bridging (innominate) vein; and 3) eval- 
uating suprasternal nd high left parasternal views looking for a left 
superior vena cava by imaging and color flow mapping. As stated in an 
earlier report (2), the diagnosis of a left superior vena cava is 
dependent on the amount of time spent looking for the structure and 
the size of the left superior vena cava. 
In summary, I appreciate the comments of Di Carlo and Marino 
and agree with the majority of the caveats that they have brought to my 
attention. 
THOMAS M. ZELLERS, MD, FACC 
Ct, ildren's Medical Center of Dallas 
1935 Motor Street 
Dallas, Texas 75235 
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Liposomal Prostaglandin E~ Does Not 
Reduce Myocardial Infarct Size in 
Anesthetized Dogs 
In the :eport by Feid et al. (1), the authors c~J clude that liposomal 
prostaglandin E reduces myocardial infarct size as a result of myo- 
cardial ischemia nd reperfusion i a canine thrombolysis model. This 
conclusion is based in large part on the relation of myocardial infarct 
size to epicardial coronary collateral blood flow, as shown in Figure 3 
of the article. 
It is well known that myocardial infarct size in anesthetized dogs is 
inversely related to coronary collateral blood flow (2). For example, in 
a canine model with ---2 h of myocardial isehemia followed by 96 h of 
reperfusion, dogs with high epicardial coronary collateral blood flow 
(>0.30 ml/min per g) demonstrated small infarctions (17 +- 2% of area 
at risk), whereas those with low epicardial coronary collateral blood 
flow (<0.30 ml/min per g) demonstrated myocardial infarctions of 
34 _+_ 3% of the area at risk (3). Feld et al. seem well aware of this 
relation and analyzed myocardial infarct size using an analysis of 
covariance with collateral blood flow as a covariate. 
In the Feld et al. study, one of six placebo-treated dogs demon- 
strated high epicardial coronary collateral blood flow; yet, a relatively 
large infarction was noted in this animal, which is inconsistent with its 
high coronary collateral blood flow. Although this dog is clearly not 
representative of the placebo-treated group, it was included in the 
analysis and strongly influenced the regression describing the placebo 
response. Importantly, it was on the basis of this nonrepresentative 
placebo-treated do~ that the authors concluded, tk~t I.L~Q~m.~,~- 
tagfandfn ET~ reduced myocardial infarct fize. We suggest hat this 
conclusion is wrong because, with the exception of this nonrepresen- 
tative dog, the placebo and liposomal prostaglandin E, treatment 
groups appear to duster about the same regression line. Thus, the 
apparent protective effect of liposomal prostaglandin E~ on myocardial 
infarct size reported by Feld et al. appears to be due to erroneous 
inclusion of anomalous placebo treatment data. 
JOHN E. KOERNER, PHD 
MARYANN GORDON, MD 
Public Health Sen, ice 
Food and Drug Administration 
Rockville, Maryland 20857 
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~pty 
The principal findings of our study (1) were that 1) !iposomal pros- 
taglandin E~ (TLC C-53) accelerated the time to thrombolysis of a 
Figure I. Relation between infarct size, normalized to area at risk, in 
control dogs and baseline central ischemic collateral blood flow 
illustrated for the conscious model. (Reproduced from Reimer et al. 
[3] with permission.) 
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Figure 2. Infarct salvage with liposomal prostaglandin El 
0)- 
coil-induced thrombus; 2) improved epicardial blood flow and micro- 
vascular perfusion of the infarct zone; and 3) reduced neutrophil 
infi trafion of ischemic myocardium, leading to a reduction in infarct 
size. Because the severity and duration of ischemia re the major 
determinants of infarct size (2), it should not be surprising that some 
dogs with a greater ischemic insult have a relatively larger infarct 
despite higher epicardial collateral f ow during ischemia. In fact, the 
placebo dog considered to be nonrepresentative by Koemer and 
Gordon had delayed coronary thrombolysis and early reocdusion, 
The study by Reimer et al. (3), cited by Koemer and Gordon, 
involved acanine model of uniform duration of coronary occlusion a~d 
demonstrated aninverse relation of infarct size as a percent of risk 
region and collateral f ow. Among control dogs subjected to perma- 
nent coronary occiusion (Fig. 1), one dog had a similar infarct size 
despite higher collateral f ow than our "nonrepresentative" dog (Fig. 
2). The treatment group in the study by Reimer et al. (3) included one 
dog with a considerably larger infarct (60% of the risk region) with the 
highest collateral f ow (nearly 1.2 ml/min per g). Even after reanaly- 
zation of our data excluding the dog with higher epicardial f ow, there 
still is a significant reduction (p < 0.05) in infarct size with TLC C-53 
by analysis of covariance. Furthermore, the mean transmural blood 
flow into the ischemic region during coronary occlusion for all dogs 
included in our study was <0.4 ml/min per g, which corresponds tothe 
level of flow at which myocardial necrosis first evident. As mentioned 
in the text of our report (1), when transmural collateral blood flow to 
the ischemic region was used as a covariate, infar:t size was also 
significantly smaller (p < 0.05) with TLC C-53. Once again, the 
significance by analysis of covariance was unaltered after exclusion of 
the dog whose mean ischemic zone transmural blood flow during 
occlusion was 0.34 ml/min per g. 
We conclude that the administration of TLC C-53 resulted in 
infarct salvage in our study. 
STEVEN FELD, MD 
RICHARD W. SMALLiNG, MD, PHD, FACC 
Division ol Cardiology 
The University of Texas Health Science Center 
6431 Fann#z 
Houston, Texas 77030 
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ABIM ANNOUNCEMENT REGARDING BOARD ELIGIBILITY 
The American Board of Internal Medicine is planning te undertake a complete review of its 
policies concerning Board Eligibility. The ABIM anticipates that revised Board Eligibility 
policies will be announced by December 31, 1996. 
In the interim, the rule ~ concerning the duration and reestablishment of the Board Eligible 
status will be suspended. All candidates with this status will continue to be regarded as Board 
Eligible and therefore able to sit for the Certifying Examinations in internal medicine or the 
subspecialties. However, the Board's Qualifying Examination, developed to reestablish Board 
Eligibility, will not be offered. 
Candidates who have questions about this policy should contact he American Board of 
Internal Medicine, 3624 Market Street, Philadelphia, PA 19104-2675 (1-800-441-2246). 
